Vanguard Group’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-13,097,546
| Closed | -$79M | – | 4133 |
|
|
2019
Q4 | $79M | Buy |
13,097,546
+831,697
| +7% | +$4.81M | ﹤0.01% | 1890 |
|
|
2019
Q3 | $44.2M | Buy |
12,265,849
+8,296
| +0.1% | +$32K | ﹤0.01% | 2125 |
|
|
2019
Q2 | $32.9M | Buy |
12,257,553
+324,147
| +3% | +$957K | ﹤0.01% | 2299 |
|
|
2019
Q1 | $35.3M | Buy |
11,933,406
+3,315,881
| +38% | +$8.15M | ﹤0.01% | 2257 |
|
|
2018
Q4 | $13.7M | Sell |
8,617,525
-3,096,015
| -26% | -$8.75M | ﹤0.01% | 2613 |
|
|
2018
Q3 | $43.1M | Buy |
11,713,540
+601,486
| +5% | +$1.79M | ﹤0.01% | 2216 |
|
|
2018
Q2 | $31.4M | Buy |
11,112,054
+254,241
| +2% | +$866K | ﹤0.01% | 2360 |
|
|
2018
Q1 | $40.3M | Buy |
10,857,813
+48,818
| +0.5% | +$160K | ﹤0.01% | 2182 |
|
|
2017
Q4 | $31.1M | Buy |
10,808,995
+1,391,152
| +15% | +$5.05M | ﹤0.01% | 2304 |
|
|
2017
Q3 | $42.3M | Sell |
9,417,843
-156,492
| -2% | -$695K | ﹤0.01% | 2119 |
|
|
2017
Q2 | $43.9M | Sell |
9,574,335
-11,488
| -0.1% | -$46.2K | ﹤0.01% | 2070 |
|
|
2017
Q1 | $40.4M | Buy |
9,585,823
+646,415
| +7% | +$2.68M | ﹤0.01% | 2108 |
|
|
2016
Q4 | $36.9M | Buy |
8,939,408
+274,451
| +3% | +$1.46M | ﹤0.01% | 2125 |
|
|
2016
Q3 | $70.2M | Buy |
8,664,957
+210,244
| +2% | +$1.79M | ﹤0.01% | 1773 |
|
|
2016
Q2 | $65.9M | Buy |
8,454,713
+455,251
| +6% | +$3.91M | ﹤0.01% | 1773 |
|
|
2016
Q1 | $61.8M | Buy |
7,999,462
+316,841
| +4% | +$2.32M | ﹤0.01% | 1764 |
|
|
2015
Q4 | $82.9M | Buy |
7,682,621
+311,482
| +4% | +$2.83M | 0.01% | 1587 |
|
|
2015
Q3 | $50.9M | Buy |
7,371,139
+482,122
| +7% | +$3.93M | ﹤0.01% | 1859 |
|
|
2015
Q2 | $61M | Buy |
6,889,017
+418,588
| +6% | +$3.96M | ﹤0.01% | 1828 |
|
|
2015
Q1 | $63.8M | Buy |
6,470,429
+984,408
| +18% | +$12.3M | ﹤0.01% | 1795 |
|
|
2014
Q4 | $67.2M | Buy |
5,486,021
+488,206
| +10% | +$5.96M | ﹤0.01% | 1682 |
|
|
2014
Q3 | $49.9M | Buy |
4,997,815
+107,821
| +2% | +$1M | ﹤0.01% | 1790 |
|
|
2014
Q2 | $37M | Sell |
4,889,994
-228,932
| -4% | -$913K | ﹤0.01% | 1979 |
|
|
2014
Q1 | $16.8M | Buy |
5,118,926
+428,383
| +9% | +$1.5M | ﹤0.01% | 2252 |
|
|
2013
Q4 | $15.6M | Buy |
4,690,543
+363,388
| +8% | +$1.05M | ﹤0.01% | 2262 |
|
|
2013
Q3 | $13.1M | Buy |
4,327,155
+148,402
| +4% | +$1.02M | ﹤0.01% | 2277 |
|
|
2013
Q2 | $34.2M | Buy |
+4,178,753
| New | +$31.9M | ﹤0.01% | 1858 |
|
Vanguard Group's ACHN Position: Q1 2020 in Review
Vanguard Group sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 13,097,546 shares — an estimated $79M sold.
Vanguard Group first reported a position in ACHN in Q2 2013 and held it in 27 quarters. The position peaked at $82.9M in Q4 2015. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- Vanguard Group reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- Vanguard Group sold 13,097,546 Achillion Pharmaceuticals shares in Q1 2020, an estimated $79M.
- Vanguard Group first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
- Vanguard Group's Achillion Pharmaceuticals position peaked at $82.9M in Q4 2015.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on Vanguard Group's 13F filing for Q1 2020, filed 15 May 2020.